罗欣药业(002793) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥646,173,009.72, representing a 3.94% increase compared to the same period last year[4] - Net profit attributable to shareholders reached ¥5,231,766.19, a significant increase of 102.96% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,617,572.43, up 101.48% from the previous year[4] - Total operating revenue for the third quarter was CNY 1,723,415,167.25, a decrease of 8.35% from CNY 1,880,916,973.62 in the previous period[21] - Net profit for the period was CNY 33,559,116.79, compared to a net loss of CNY 317,601,218.57 in the previous period[21] - The net profit attributable to the parent company is ¥22,926,815.63, a decrease from a loss of ¥265,370,489.03 in the previous period[23] - The total comprehensive income amounts to ¥61,556,785.95, compared to a loss of ¥317,388,551.03 in the previous period[23] Cash Flow - The operating cash flow net amount for the year-to-date period was ¥280,115,794.72, reflecting a substantial increase of 272.42%[4] - Operating cash flow generated from activities is ¥280,115,794.72, a significant improvement from a negative cash flow of ¥162,463,515.99 in the previous period[26] - Cash inflow from operating activities totals ¥2,024,224,167.33, up from ¥1,866,257,516.66 in the previous period[26] - Cash outflow from operating activities is ¥1,744,108,372.61, down from ¥2,028,721,032.65 in the previous period[26] - The net cash flow from investing activities is ¥43,012,421.27, an increase from ¥18,363,305.00 in the previous period[26] - The net cash flow from financing activities is -¥292,989,491.23, worsening from -¥97,785,527.09 in the previous period[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 38,267[11] - The largest shareholder, Shandong Luoxin Holdings, holds 21.79% of shares, totaling 236,955,520 shares, with 138,463,530 shares pledged[11] - The second-largest shareholder, Fang Xiubao, holds 9.22% of shares, totaling 100,294,266 shares[11] - The company approved an employee stock ownership plan allowing for a maximum of 26,027,861 shares at a grant price of 2.03 CNY per share[13] - The company plans to raise up to 842.40 million CNY through a private placement of A-shares, with a maximum issuance of 326,276,545 shares[15] - The company has not disclosed any related party relationships among the top shareholders[12] - The total number of preferred shareholders at the end of the reporting period is not applicable[13] - The company has set aside a reserve of 7,808,358 shares for the employee stock ownership plan[13] - The company will disclose further information regarding the employee stock ownership plan as it progresses[14] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[12] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥3,990,146,666.61, a decrease of 7.98% from the end of the previous year[4] - The company’s total assets decreased to CNY 3,990,146,666.61 from CNY 4,335,978,261.75, a decline of 7.94%[19] - The total liabilities decreased to CNY 2,460,056,368.74 from CNY 2,876,574,008.51, a reduction of 14.51%[19] - The company’s equity attributable to shareholders increased to CNY 1,452,480,831.45 from CNY 1,382,277,279.71, an increase of 5.06%[19] Operational Metrics - The company's basic earnings per share for Q3 2025 was ¥0.0049, up 102.94% year-on-year[4] - Basic earnings per share are ¥0.0216, compared to a loss of ¥0.2486 in the previous period[23] - Diluted earnings per share are ¥0.0213, also an improvement from a loss of ¥0.2486 in the previous period[23] - The weighted average return on equity for the year-to-date period was 1.62%, an increase of 13.37% compared to the same period last year[4] - The company reported a significant increase in other comprehensive income, which rose by 127.12% to ¥49,848,796.21[9] Cost Management - Total operating costs decreased to CNY 1,736,037,629.45 from CNY 2,162,836,623.58, reflecting a reduction of 19.66%[22] - Accounts receivable decreased to CNY 494,084,460.26 from CNY 569,106,113.41, a decline of 13.14%[18] - Inventory levels decreased to CNY 367,856,007.66 from CNY 459,555,606.49, a reduction of 20%[18] - Research and development expenses increased to CNY 63,300,332.23 from CNY 49,206,243.34, marking a rise of 28.66%[22] - The company experienced a 30.69% increase in short-term borrowings, totaling ¥969,785,853.73[9]